| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI helps detect abnormalities more precisely and consistently, reducing errors and assisting doctors in making more accurate diagnoses, which leads to better treatment outcomes for patients. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
Ai system can provide additional analysis or flag potential issues |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
The article emphasizes the importance of healthcare professionals understanding ai |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
This is a superficial factor and has no bearing on whether healthcare professionals accept or trust Ai |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
When respected colleagues, professional bodies or institutions endorse AI, individuals are likely to adopt it. Peer perception can strongly influence adoption behavior |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
None of the above |
|
Some professionals worry that Ai might eventually take over task they currently perform, leading to job insecurity or devaluation of clinical expertise |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Human centered design ensures AI tools support rather than replace professionals, aligning with their needs, values and work processes to build trust and usability. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
Ai system must be practical useful and fit seamlessly into daily routine. Otherwise they become burdensome and are unlikely to be used consistently. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
If AI systems align with ethical principles like patient autonomy, safety and fairness. Professionals are more likely to trust and use them. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
Understanding how users interact with Ai and whether it fits well into the real world settings is key to designing better tools and improving adoption. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease is caused by the loss of dopamine producing neurons. Stem cells can be engineering to become these neurons and restore brain function. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
Monkeys have brain structures closest to humans which makes them more appropriate for testing therapies intended for neurological conditions. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
12 months |
|
Long-term studies are essential to monitor for delayed adverse effects like tumor formation or cell overgrowth, ensuring the treatment’s long term safety. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
This early trial phase focuses on evaluating safety, dosage and preliminary efficacy in human participants. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
GMP ensures the safety, purity and quality of the stem cell product for human use, which is required for clinical trials. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The absence of tumors or harmful effects in long term studies indicates that the therapy is likely safe for progression to human trials. |
Safety Assessment
You must not contain tumorigenicity or toxicity before entering the clinic |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
This result suggests that the stem cell therapy restored motor function, providing strong evidence that the treatment could benefit Parkinson’s patients. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
These are molecular markers for midbrain dopamine neurons. Their presence confirms that the stem cell batch has differentiated correctly and is suitable for therapy. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b and SHH guide stem cells to differentiate into the right type of neurons. In this case, midbrain dopamine this neurons needed for Parkinson’s treatment. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
Improvement in motor skills shows the treatment is functionally effective, which is critical before testing in humans. |
Paper |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|